USANA Health Sciences (NYSE:USNA) Upgraded by ValuEngine to Hold

ValuEngine upgraded shares of USANA Health Sciences (NYSE:USNA) from a sell rating to a hold rating in a report released on Thursday, ValuEngine reports.

A number of other research firms also recently commented on USNA. Sidoti downgraded USANA Health Sciences from a buy rating to a neutral rating and set a $70.00 target price on the stock. in a research report on Wednesday, July 3rd. TheStreet downgraded USANA Health Sciences from a b- rating to a c+ rating in a research report on Thursday, July 11th. Tigress Financial began coverage on USANA Health Sciences in a research report on Tuesday, April 16th. They issued a buy rating on the stock. Finally, Pivotal Research restated a buy rating on shares of USANA Health Sciences in a research report on Wednesday, July 24th. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $72.50.

USANA Health Sciences stock traded down $0.18 during trading on Thursday, reaching $68.35. 381,257 shares of the company were exchanged, compared to its average volume of 365,310. USANA Health Sciences has a 52-week low of $58.30 and a 52-week high of $134.65. The firm has a market capitalization of $1.60 billion, a P/E ratio of 15.30 and a beta of 0.44. The firm’s 50 day moving average price is $67.74.

USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, July 23rd. The company reported $0.91 EPS for the quarter, missing the Zacks’ consensus estimate of $0.93 by ($0.02). USANA Health Sciences had a net margin of 9.68% and a return on equity of 26.85%. The business had revenue of $256.00 million during the quarter, compared to analysts’ expectations of $254.66 million. During the same quarter in the prior year, the firm earned $1.36 EPS. USANA Health Sciences’s revenue for the quarter was down 15.1% compared to the same quarter last year. On average, sell-side analysts expect that USANA Health Sciences will post 3.9 EPS for the current year.

A number of large investors have recently bought and sold shares of the business. MERIAN GLOBAL INVESTORS UK Ltd grew its stake in shares of USANA Health Sciences by 54.1% in the first quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 363,410 shares of the company’s stock valued at $30,479,000 after buying an additional 127,543 shares in the last quarter. Norges Bank acquired a new stake in shares of USANA Health Sciences in the fourth quarter valued at $35,531,000. Robeco Institutional Asset Management B.V. grew its stake in shares of USANA Health Sciences by 3.4% in the first quarter. Robeco Institutional Asset Management B.V. now owns 246,416 shares of the company’s stock valued at $20,665,000 after buying an additional 8,205 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of USANA Health Sciences by 6.7% in the fourth quarter. Geode Capital Management LLC now owns 199,021 shares of the company’s stock valued at $23,430,000 after buying an additional 12,445 shares in the last quarter. Finally, Federated Investors Inc. PA grew its stake in shares of USANA Health Sciences by 16.1% in the first quarter. Federated Investors Inc. PA now owns 114,283 shares of the company’s stock valued at $9,585,000 after buying an additional 15,881 shares in the last quarter. Institutional investors own 59.13% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Featured Story: What is Depreciation?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.